Artelo Biosciences announced a $9.475 million private sale plan to launch its Solana financial strategy.

PANews, September 9 - Nasdaq-listed company Artelo Biosciences (Nasdaq: ARTL) announced the launch of a public offering of common stock and/or pre-funded warrants, with R.F. Lafferty & Co., Inc. serving as the sole bookrunner. In addition, Artelo announced a private fundraising plan worth $9.475 million, which will initiate financial strategies based on the Solana blockchain, becoming one of the first companies to adopt Solana cryptocurrency as a core reserve asset.

SOL1.33%
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Related Topics
#
sol
Comment
0/400
No comments
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)